PMS for cancer drugs faces several challenges, including:
Patient diversity: Cancer patients often have varying genetic backgrounds and comorbidities, making it challenging to generalize findings. Long-term follow-up: Some side effects may take years to manifest, requiring extended periods of monitoring. Data collection: Ensuring accurate and comprehensive data collection can be difficult, especially in real-world settings. Regulatory compliance: Different countries have different regulations, complicating global surveillance efforts.
